China Pharma Holdings

Historical price data

China Pharma Holdings operates as an integrated generic pharmaceutical manufacturer in China, with a mission to provide affordable, standardized medicines for widespread therapeutic needs. Its strategy is centered on cost-effective production of small-molecule dosage forms, from API processing to final packaging, for the domestic healthcare market. However, the company has achieved limited commercial success, evidenced by a negligible market capitalization, lack of a functional corporate website, and substantial operational and financial headwinds. Its primary achievement remains maintaining a publicly listed status on NASDAQ despite these severe difficulties.

Integrated manufacturing infrastructure for small-molecule generic pharmaceuticals, focusing on cost-effective production of finished dosage forms (tablets, capsules, powders, ointments) compliant with Chinese regulatory standards.

Operates in the highly consolidated and competitive Chinese generic market, dominated by large domestic giants (e.g., Sinopharm, CSPC) and multinationals. As a small, undifferentiated player with financial constraints, it lacks the scale, portfolio breadth, and cost advantages needed to compete effectively under current market policies.